FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DС	20549
vvasiliigton,	D.O.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

	tions may conti ction 1(b).	nue. See		Filed	pursua or Se	ant t	to Sect	ion 16(a) of the	Secur ent Co	ities Exchange	e Act o f 1940	f 1934	ļ.		hours	per respo	onse:	0.5		
1. Name and Address of Reporting Person* <u>BIOTECH TARGET N V</u>						2. Issuer Name and Ticker or Trading Symbol MACROGENICS INC [MGNX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner							
(Last) (First) (Middle) ARA HILL TOP BUILDING, UNIT A-5,						3. Date of Earliest Transaction (Month/Day/Year) 10/19/2022								Officer (give title Other (speci below) below)							
PLETTERIJWEG OOST 1							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CURACAO P8 00000														Form filed by One Reporting Person X Form filed by More than One Reporting Person							
(City) (State) (Zip)																					
Title of	Socurity (Inc		l - No	on-Deriva		_	. Deem		quirec	l, Dis	sposed of				Own		6. Own	orehin	7. Nature		
Da			Date (Month/Day		ear) Exec		cution Date,		ction Instr.	Disposed Of	f (D) (Instr. 3, 4		4 and 5)	Securities Beneficially Owned Following Reported Transaction(s)		Form: Direct (D) or Indirect (I) (Instr. 4)	Direct ndirect	of Indirect Beneficial Ownershi (Instr. 4)			
			10/10/2					Code	٧	Amount	(A) o	_	(Instr.		3 and 4)						
Common Stock				10/19/2022				P P		168,422 285,977	A	<u> </u>	3.7045			D D					
					ive Securities Acc			Αςαι		Dier		ļ									
		14	DIC II								convertib				WIIC						
. Title of Derivative Security Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) i	Execu if any	eemed ition Date, h/Day/Year)	4. Transaction Code (Instr. 8)		on of tr. De Se Ad (A Di of			e Exer ation D h/Day/		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficia Ownersh t (Instr. 4)		
					Code	v	(A) (D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	per							
		f Reporting Person*	•				,	,						,			,		•		
	LL TOP BU	(First) UILDING, UNIT	•	liddle)																	
(Street)	AO	P8	00	0000																	
(City)		(State)	(Zi	ip)																	
	nd Address of	f Reporting Person*	•																		
(Last) SCHWE	RTSTRAS	(First) SE 6	(M	liddle)																	
(Street)	FHAUSEN	V8	C	H-8200		_															

Explanation of Responses:

(State)

(Zip)

(City)

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Macrogenics, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.

10/21/2022 /s/Daniel Koller /s/Martin Gubler 10/21/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.